CN106362088A - Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis - Google Patents
Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis Download PDFInfo
- Publication number
- CN106362088A CN106362088A CN201610842842.0A CN201610842842A CN106362088A CN 106362088 A CN106362088 A CN 106362088A CN 201610842842 A CN201610842842 A CN 201610842842A CN 106362088 A CN106362088 A CN 106362088A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- parts
- medicine composition
- liver cirrhosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 26
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 22
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 10
- 206010008909 Chronic Hepatitis Diseases 0.000 title claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims abstract description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 45
- 241000756943 Codonopsis Species 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 241000736919 Pelodiscus sinensis Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000010411 cooking Methods 0.000 claims description 2
- -1 electuary Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 3
- 206010062713 Haemorrhagic diathesis Diseases 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 239000012567 medical material Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 9
- 206010016654 Fibrosis Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 230000004761 fibrosis Effects 0.000 abstract description 7
- 210000000952 spleen Anatomy 0.000 abstract description 6
- 208000019423 liver disease Diseases 0.000 abstract description 5
- 230000002440 hepatic effect Effects 0.000 abstract description 4
- 208000031971 Yin Deficiency Diseases 0.000 abstract description 3
- 231100000283 hepatitis Toxicity 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 235000014375 Curcuma Nutrition 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 230000003393 splenic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 11
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000164439 Curcuma angustifolia Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Provided is a traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis. The medicine combination consists of 12 traditional Chinese medicine constituents, radix astragali, radix condonopsis, angelica sinensis, radix paeoniae alba, radix curcumae, salvia miltiorrhiza, turtle shell, tortoiseshell, caulis spatholobi, rhizome sparganii, curcuma zedoary, peach kernel and more. The medicine combination can be prepared into various oral preparations such as health care product, food product, admixture, pills, tablets, capsules, granules and more. The traditional Chinese medicine combination is clinically proved to have outstanding treatment effects on patients with a variety of hepatoses, especially on patients with chronic hepatitis accompanied by fibrotic lesions or liver cirrhosis not accompanied by hemorrhagic tendencies. The traditional Chinese medicine combination employs traditional Chinese medicine treatment theory; patients are diagnosed and treated by arguments of blood stasis due to stagnation of qi, hepatic stagnation causing splenic deficiency, hypofunctioning of spleen and stomach, hepatic and renal yin deficiency, toxin generated by accumulation of damp heat, and others. The traditional Chinese medicine combination starts with etiology and pathogenesis, and treats with soothing liver and strengthening spleen, promoting qi to activate blood, dissolving stasis and eliminating symptoms, nourishing liver and kidney, cooling blood and eliminating stasis. The traditional Chinese medicine combination has a good clinical curative effect on symptoms like hepatitis fibrosis and liver cirrhosis.
Description
Technical field
The invention discloses a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis, it belongs to Chinese medicine group
Compound technical field.
Background technology
The total incidence of hepatitis occupy the first place of all kinds of infectious disease of China always, viral hepatitis especially hepatitis B (hbv)
Popular extensively, the serious harm human health in China, is one of China's public health problem the most prominent at this stage.Currently,
China there are about 1.2 hundred million hepatitis B virus carrierss, and about 20% the infected becomes chronic carriers or hepatitis B patient.Chronic hepatitiss
In pathogeny, because immunoreation causes hepatic injury, and the persistent infection of virus leads to chronicity, fibrosiss or even forms liver
Hardening, hepatocarcinoma.Liver fibrosis are that hepatocyte necroses and during inflammatory stimulus, fibrous connective tissue paraplasm in liver
Caused pathological process, is also various chronic hepatopathy necessarily passing to cirrhosis progress.If in diagnosis early stage and giving to resist
Treatment of fibrosis, can delay progression of disease, reduce and prevent sending out of Liver failure, liver cirrhosis, hepatocarcinoma and its complication
Raw, thus extending patient survival and quality of making the life better.
Hepatic fibrosis are the common pathological characters of various chronic hepatopathys.For the treatment of viral hepatitis, famous American liver
Sick scholar hans popper points out: " who can stop or delay hepatic fibrosis to occur, and who will cure most of hepatopathys ".Fine with liver
Gradually illustrating of dimensionization pathogenesis, makes treatment be possibly realized, but current doctor trained in Western medicine there is no good medicine, Colchicine,
The curative effects such as ketone theobromine are low, erious adverse reaction, are limited to the experimentation stage more.Chinese medicine is to hepatocyte inflammation, necrosis and liver
Fibrosiss etc. have good action.Wang Baoen etc. catches the essence of hepatic fibrosis " blood stasis ", promoting blood circulation based on Radix Salviae Miltiorrhizae for the application
Stasis of blood Chinese medicine compound is treated to Experimental Liver Fibrosis, receives different degrees of mitigation or reverse hepatic fibrosis curative effect.
Content of the invention
The present invention provides a kind of Chinese medicine composition, can effectively prevent or treat the hepatic fibrosis of chronic hepatitiss initiation, and liver is hard
Change and be particularly suited for qi depression to blood stasis, stagnation of liver-QI with deficiency of the spleen, the hepatic fibrosis of hepatic and renal YIN deficiency initiation and liver cirrhosis.This pharmaceutical composition by under
The component stating weight proportion is made:
Radix Astragali 1-20 part, Radix Codonopsis 1-15 part, Radix Angelicae Sinensis 1-10 part, Radix Paeoniae Alba 1-10 part, Radix Curcumae 3-15 part, Radix Salviae Miltiorrhizae 1-20 part, Trionyx sinensis Wiegmann
First 1-20 part, Carapax et Plastrum Testudiniss 1-10 part, Caulis Spatholobi 1-15 part Rhizoma Sparganii 1-15 part, Rhizoma Curcumae 1-10 part, Semen Persicae 1-15 part.
Preferably pharmaceutical composition is made up of the component of following weight proportioning:
Radix Astragali 4-12 part, Radix Codonopsis 3-10 part, Radix Angelicae Sinensis 3-10 part, Radix Paeoniae Alba 3-10 part, Radix Curcumae 3-8 part, Radix Salviae Miltiorrhizae 2-10 part, Carapax Trionycis
5-12 part, Carapax et Plastrum Testudiniss 2-6 part, Caulis Spatholobi 4-10 part, Rhizoma Sparganii 3-9 part, Rhizoma Curcumae 2-8 part, Semen Persicae 2-8 part.
Most preferably pharmaceutical composition is made up of the component of following weight proportioning:
8 parts of the Radix Astragali, 6 parts of Radix Codonopsis, 6 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 6 parts of Radix Curcumae, 6 parts of Radix Salviae Miltiorrhizae, 8 parts of Carapax Trionycis, 4 parts of Carapax et Plastrum Testudiniss, Caulis Spatholobi 6
Part, 6 parts of Rhizoma Sparganii, 6 parts of Rhizoma Curcumae, 6 parts of Semen Persicae.
Of the present invention a kind of treat hepatic fibrosis, the Chinese medicine composition of liver cirrhosis can be prepared as various
The health product of dosage form, food or medicament, including but not limited to: decoction, tablet, sugar coated tablet, film coated tablet, enteric coated tablet
Agent, capsule, hard capsule, soft capsule, oral liquid, mouth containing agent, granule, electuary, pill, powder, sublimed preparation, suspensoid,
Powder, solution, injection and drop etc..
Wherein, a kind of preferred agent of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis of the present invention
Type is mixture, capsule, granule, tablet, and preparation method is relatively simple, taking convenience, and patient clinical compliance is good.Its preparation
Method comprises the following steps:
Above medicine, plus 6-12 times amount decocting boils 1-3 time, each 1-3 hour, collecting decoction, filtration, can suitably concentrate, obtain final product
Decoction.If being prepared as other dosage forms, concentrating filtrate, extracting thick paste using decocting cooking method, drying under reduced pressure, pulverize, obtain dry extract
Powder, adds adjuvant, mix homogeneously, pelletizes, and tabletting or encapsulated obtains final product.
Present invention also includes this Chinese medicine composition and answers in the clinic of preparation prevention or treatment hepatic fibrosis
With.
The application has the beneficial effect that this Chinese medicine composition, by Chinese medicine ingredients such as the Radix Astragali, Radix Codonopsis, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Curcumaes
Composition, can need to be prepared into the various oral agents such as health product, food, mixture, pill, tablet, capsule, granule according to clinic
Type.This Chinese medicine composition inclines without bleeding with fibrosis lesion or liver cirrhosis for hepatic diseases, especially chronic hepatitiss
To patient there is very excellent therapeutical effect.This Chinese medicine composition adopts Chinese medicine theoretical, from qi depression to blood stasis, stagnation of liver-QI
The dialectical treatmert such as insufficiency of the spleen, weakness of the spleen and stomach, the hepatic and renal YIN deficiency, damp and hot residual poison, starts with from etiology and pathogenesis, with soothing liver and strengthening spleen, promoting flow of QI and blood,
Blood stasis dispelling eliminating mass, nourishing the liver and kidney, removing heat from blood repercussive control it, good to hepatitis fibrosiss, hepatocirrhosis symptoms clinical efficacy.
Specific embodiment
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following examples.Specifically
Embodiment:
Prepared by Part I Chinese medicinal composition preparation of the present invention.
Embodiment 1 mixture
Prescription: 6 parts of the Radix Astragali, 5 parts of Radix Codonopsis, 5 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 4 parts of Radix Curcumae, 6 parts of Radix Salviae Miltiorrhizae, 8 parts of Carapax Trionycis, 2 parts of Carapax et Plastrum Testudiniss, chicken
4 parts of Caulis seu Radix Schisandrae Henryi, 6 parts of Rhizoma Sparganii, 4 parts of Rhizoma Curcumae, 3 parts of Semen Persicae.
Preparation method: above medicine, add water to cook twice, each 1-3 hour, collecting decoction, filtration, clear filtrate is concentrated into phase
It is 1.05～1.10 to density, add preservative, fill to obtain final product mixture.
Embodiment 2 granule
Prescription: 4 parts of the Radix Astragali, 6 parts of Radix Codonopsis, 5 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 4 parts of Radix Curcumae, 4 parts of Radix Salviae Miltiorrhizae, 6 parts of Carapax Trionycis, 2 parts of Carapax et Plastrum Testudiniss, chicken
6 parts of Caulis seu Radix Schisandrae Henryi, 6 parts of Rhizoma Sparganii, 5 parts of Rhizoma Curcumae, 5 parts of Semen Persicae.
Preparation method: above medicine, add water to cook twice, each 1-3 hour, collecting decoction, filtration, filtrate concentrates, extraction is thick
Cream, drying under reduced pressure, pulverize, obtain dry extract, according to common process plus dextrin, cane sugar powder, mix, make granule and obtain final product.
Embodiment 3 tablet
Prescription: 8 parts of the Radix Astragali, 4 parts of Radix Codonopsis, 4 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 4 parts of Radix Curcumae, 4 parts of Radix Salviae Miltiorrhizae, 2 parts of Carapax Trionycis, 4 parts of Carapax et Plastrum Testudiniss, chicken
6 parts of Caulis seu Radix Schisandrae Henryi, 5 parts of Rhizoma Sparganii, 5 parts of Rhizoma Curcumae, 5 parts of Semen Persicae.
Preparation method: above medicine, add water to cook twice, each 1-3 hour, collecting decoction, filtration, filtrate concentrates, extraction is thick
Cream, drying under reduced pressure, pulverize, obtain dry extract.Take above-mentioned dry extract, add Pulvis Talci, amylum pregelatinisatum according to common process,
Mix homogeneously, tabletting obtains final product.
Embodiment 4 capsule
Prescription: 5 parts of the Radix Astragali, 4 parts of Radix Codonopsis, 4 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 4 parts of Radix Curcumae, 4 parts of Radix Salviae Miltiorrhizae, 6 parts of Carapax Trionycis, 2 parts of Carapax et Plastrum Testudiniss, chicken
5 parts of Caulis seu Radix Schisandrae Henryi, 5 parts of Rhizoma Sparganii, 5 parts of Rhizoma Curcumae, 5 parts of Semen Persicae.
Preparation method: above medicine, add water to cook twice, each 1-3 hour, collecting decoction, filtration, filtrate concentrates, extraction is thick
Cream, drying under reduced pressure, pulverize, obtain dry extract.Take above-mentioned dry extract, add Pulvis Talci, starch according to common process, mixing is all
Even, pelletize, encapsulated, obtain final product capsule.
Embodiment 5 decoction
Prescription: 8 parts of the Radix Astragali, 6 parts of Radix Codonopsis, 4 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 4 parts of Radix Curcumae, 2 parts of Radix Salviae Miltiorrhizae, 4 parts of Carapax Trionycis, 6 parts of Carapax et Plastrum Testudiniss, chicken
6 parts of Caulis seu Radix Schisandrae Henryi, 5 parts of Rhizoma Sparganii, 2 parts of Rhizoma Curcumae, 4 parts of Semen Persicae.
Preparation method: above medicine, add water to cook twice, each 1-3 hour, collecting decoction, remove solid residue, you can be obtained
The decoction of the present invention.
Part II Chinese medicine composition of the present invention pharmacodynamic study
The therapeutical effect to Rat Liver Fibrosis Model for the Chinese medicine composition of the present invention, fine with serum alt, ast activity and serum
Dimensionization mark laminin (ln), hyaluronic acid (ha), procollagen type Ⅲ (pc) are as evaluation index.
Health male cleaning grade sd rat 72, body weight 200 ± 20g, it is divided into blank control group, model control group, autumn waters -- limid eyes
Celestial alkali group, 1 group of embodiment, 2 groups of embodiment, 3 groups of embodiment.After adaptability is raised one week, in addition to blank control group, subcutaneous injection
ccl4(use 40% ccl first4Oil solution presses 0.5ml/100g dosage, presses 0.3ml/100g dosage every 3 days later, and altogether 6
Week).Normal diet feeds rat, free water.Modeling starts simultaneously at administration (see Table 1), and blank control group, model group give
Amount normal saline gavage, remaining each group gives embodiment Chinese medicine composition, once a day.Successive administration terminated to the modeling same period,
The last time after administration 24h, deep anaesthesia puts to death laboratory animal, and vein maximum measures blood, and 4 DEG C of centrifugation serum are used for
The mensure of serum alt, ast.Serum Fibrosis mark laminin (ln), hyaluronic acid (ha), procollagen type Ⅲ (pc
) detection carried out using radioimmunology, operated in strict accordance with kit specification.
Table 1 each group administration title and dose form
| Packet | Administration title | Administering mode | Dosage |
| Blank control group | Normal saline | Gavage | 1ml/100g |
| Model control group | Normal saline | Gavage | 1ml/100g |
| Colchicine group | Colchicine suspension | Gavage | 0.125mg/kg |
| 1 group of embodiment | Chinese medicine composition suspension | Gavage | 10.5g/kg |
| 2 groups of embodiment | Chinese medicine composition suspension | Gavage | 10.5g/kg |
| 3 groups of embodiment | Chinese medicine composition suspension | Gavage | 10.5g/kg |
Note: Colchicine group is equivalent to 5 times of adult human dose, Chinese medicine composition suspension dosage is equivalent to 5 times of adult human dose.
Test result indicate that alt, ast activity in model control group rat blood serum is significantly raised compared with blank control group, control
After treating medication, alt, ast release in Chinese medicine composition embodiment 1-3 group serum of the present invention all significantly reduces, with model control group
Comparing difference statistically significant (* * p < 0.01, * p < 0.05).Model control group Serum Fibrosis mark ln, ha, pc are relatively
Blank control group is significantly raised, after medicine for treatment, ln, ha, pc content in Chinese medicine composition embodiment 1-3 group serum of the present invention
All significantly reduce, poor with model control group different statistically significant (* * p < 0.01, * p < 0.05).It is shown in Table 2-3.
The impact to serum alt, ast activity for table 2 Chinese medicine composition of the present invention
| Packet | Quantity | alt | ast |
| Blank control group | 12 | 48.07±6.25** | 152.87±34.16** |
| Model control group | 12 | 324.46±60.23 | 308.86±86.90 |
| Colchicine group | 12 | 60.88±9.61** | 200.76±37.07* |
| 1 group of embodiment | 12 | 59.36±12.74** | 185.24±31.28* |
| 2 groups of embodiment | 12 | 67.18±11.32** | 190.76±40.01* |
| 3 groups of embodiment | 12 | 62.35±10.61** | 177.59±36.20* |
The impact to serum ln, ha, pc activity for table 3 Chinese medicine composition of the present invention
| Packet | Quantity | ln | ha |
| Blank control group | 12 | 60.07±4.25** | 160.17±18.87** |
| Model control group | 12 | 87.33±6.76 | 296.35±35.94 |
| Colchicine group | 12 | 74.18±6.59** | 215.21±30.08** |
| 1 group of embodiment | 12 | 70.35±6.20** | 200.65±25.89** |
| 2 groups of embodiment | 12 | 73.09±8.26** | 211.27±20.68** |
| 3 groups of embodiment | 12 | 71.62±7.87** | 225.40±24.05** |
Claims (9)
1. a kind of treat hepatic fibrosis, liver cirrhosis Chinese medicine composition it is characterised in that described Chinese medicine composition by
The component of following weight proportioning is made:
Radix Astragali 1-20 part, Radix Codonopsis 1-15 part, Radix Angelicae Sinensis 1-10 part, Radix Paeoniae Alba 1-10 part, Radix Curcumae 3-15 part, Radix Salviae Miltiorrhizae 1-20 part, Trionyx sinensis Wiegmann
First 1-20 part, Carapax et Plastrum Testudiniss 1-10 part, Caulis Spatholobi 1-15 part Rhizoma Sparganii 1-15 part, Rhizoma Curcumae 1-10 part, Semen Persicae 1-15 part.
2. a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 1, its feature
It is, each raw material of described Chinese medicine composition is made up of the component of following weight proportioning:
Radix Astragali 4-12 part, Radix Codonopsis 3-10 part, Radix Angelicae Sinensis 3-10 part, Radix Paeoniae Alba 3-10 part, Radix Curcumae 3-8 part, Radix Salviae Miltiorrhizae 2-10 part, Carapax Trionycis
5-12 part, Carapax et Plastrum Testudiniss 2-6 part, Caulis Spatholobi 4-10 part, Rhizoma Sparganii 3-9 part, Rhizoma Curcumae 2-8 part, Semen Persicae 2-8 part.
3. a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 1, its feature
It is, each raw material of described Chinese medicine composition is made up of the component of following weight proportioning:
Radix Astragali 6-10 part, Radix Codonopsis 5-8 part, Radix Angelicae Sinensis 5-7 part, Radix Paeoniae Alba 5-8 part, Radix Curcumae 4-7 part, Radix Salviae Miltiorrhizae 5-8 part, Carapax Trionycis 6-9
Part, Carapax et Plastrum Testudiniss 3-5 part, Caulis Spatholobi 5-8 part, Rhizoma Sparganii 5-8 part, Rhizoma Curcumae 5-7 part, Semen Persicae 4-7 part.
4. a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 1-3, it is special
Levy and be, each raw material of described Chinese medicine composition is made up of the component of following weight proportioning:
8 parts of the Radix Astragali, 6 parts of Radix Codonopsis, 6 parts of Radix Angelicae Sinensis, 6 parts of the Radix Paeoniae Alba, 6 parts of Radix Curcumae, 6 parts of Radix Salviae Miltiorrhizae, 8 parts of Carapax Trionycis, 4 parts of Carapax et Plastrum Testudiniss, Caulis Spatholobi 6
Part, 6 parts of Rhizoma Sparganii, 6 parts of Rhizoma Curcumae, 6 parts of Semen Persicae.
5. a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 1-4, it is special
Levy and be: described Chinese medicine composition is used for preparing health product, food or medicament, described health product, food or medicament are decoction, mouth
Take liquid, mixture, tablet, capsule, granule, electuary, pill, powder, sublimed preparation, suspensoid, injection or drop pill.
6. the preparation of a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 1-4
Method, comprises the following steps:
(1) weigh appropriate medical material in proportion, plus 6-12 times amount decocting boils；
(2) decoct 1-3 time, each 1-3 hour；
(3) collecting decoction, filtration；
(4) concentrate, drying under reduced pressure, obtain final product decoction.
If being 7. prepared as other dosage forms, concentrating filtrate, extracting thick paste using decocting cooking method, drying under reduced pressure, pulverize, obtain dry extract
Powder, adds adjuvant, mix homogeneously, pelletizes, and tabletting or encapsulated obtains final product.
8. the application of a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 1-6,
It is characterized in that: described Chinese medicine composition has treatment hepatic fibrosis, the purposes of liver cirrhosis.
9. the application of a kind of Chinese medicine composition treating hepatic fibrosis, liver cirrhosis according to claim 7, its
It is characterised by: described chronic hepatitiss have proliferation of fibrous tissue evidence or formed the clinical condition without bleeding tendency for the liver cirrhosis
Wait.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610842842.0A CN106362088A (en) | 2016-09-23 | 2016-09-23 | Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610842842.0A CN106362088A (en) | 2016-09-23 | 2016-09-23 | Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106362088A true CN106362088A (en) | 2017-02-01 |
Family
ID=57898181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610842842.0A Pending CN106362088A (en) | 2016-09-23 | 2016-09-23 | Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106362088A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109364213A (en) * | 2018-11-23 | 2019-02-22 | 厦门市中医院 | A kind of herbal mixture for treating liver fibrosis |
| RU2684111C1 (en) * | 2018-02-07 | 2019-04-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Method for preparing medicine with methionine and turmeric extract in granular type with intestinal sustainable coating of system action |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274464A (en) * | 2011-08-10 | 2011-12-14 | 马彦秀 | Chinese medicinal composition for treating chronic hepatitis, splenauxe and cirrhosis |
-
2016
- 2016-09-23 CN CN201610842842.0A patent/CN106362088A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274464A (en) * | 2011-08-10 | 2011-12-14 | 马彦秀 | Chinese medicinal composition for treating chronic hepatitis, splenauxe and cirrhosis |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2684111C1 (en) * | 2018-02-07 | 2019-04-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Method for preparing medicine with methionine and turmeric extract in granular type with intestinal sustainable coating of system action |
| CN109364213A (en) * | 2018-11-23 | 2019-02-22 | 厦门市中医院 | A kind of herbal mixture for treating liver fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1683001A (en) | Chinese medicine for treating gout | |
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101708297A (en) | Medicament for treating gout disease | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN106362088A (en) | Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN103372073A (en) | Red rice and hawthorn medicinal composition for regulating blood fat and preparation method of composition | |
| CN100341547C (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| CN102949659B (en) | Traditional Chinese medicine composition for treating hepatitis B | |
| CN101983695A (en) | Traditional Chinese medicine composition for curing hemiplegia and preparation method thereof | |
| CN1246031C (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN111643557B (en) | Pharmaceutical composition for preventing and treating sequela of deep venous thrombosis of lower limbs and preparation method and application thereof | |
| CN107898947A (en) | A kind of herb composition for treating gout, hyperuricemia and its preparation method and application | |
| CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
| CN103405574B (en) | Medicinal composition for treating hypertension | |
| CN106237263A (en) | A kind of treat acute icterohepatitis and Chinese medicine composition that chronic hepatitis acute onset raises with bilirubin | |
| CN102488851B (en) | Drug for treating recurrent genital herpes and preparation method thereof | |
| CN113304235A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104147270A (en) | Traditional Chinese medicine for treating acute hepatitis | |
| TWI844079B (en) | Chinese medicine composition and its preparation method and application | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition | |
| CN103372040A (en) | Red rice and hemlock parsley medicinal composition for regulating blood fat and preparation method of composition | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171122 Address after: Dalian high tech Industrial Park in Liaoning province 116000 Sata Street No. 13 15 Floor No. 10 Applicant after: Dalian bloomson biological medicine technology Co., Ltd. Applicant after: Jinzhou infectious disease hospital Address before: 121000 27 Fuzhou street, Taihe District, Liaoning, Jinzhou Applicant before: LIAONING RUNSHENG KANGTAI BIOMEDICAL TECHNOLOGY CO., LTD. Applicant before: Jinzhou infectious disease hospital |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170201 |